← All trials
NCT06956807
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Jun 30, 2027
- First posted
- May 4, 2025
- Last posted
- May 4, 2025
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ViscofanLead sponsor
- Clinica Universidad de NavarraCollaborator
- Hospital General Universitario Gregorio MarañonOfficial
- Silesian University of MedicineOfficial
- Hospital General Universitario Gregorio MarañonCollaborator
- Silesian University of MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.